Fumiyoshi Ohyanagi
Saitama Cancer Center · 108 works · 1,449 citations · h-index 22
Top works
- Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer
- EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
- Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor
- Postoperative ischemic change in bronchial stumps after primary lung cancer resection
- Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
- A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy
- Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
- Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
- First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
- Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
- Acute gefitinib-induced pneumonitis
- Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
- Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene
- EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
- Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
- Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
- Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin
- Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study ( TOPGAN 2021‐01)
- Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
- Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy